In Vitro antibacterial effects of antilipopolysaccharide DNA aptamer-C1qrs complexes

Folia Microbiologica

Volumn 53, Issue 4, 2008, Pages 295-302

  Bruno, J G ^a   Carrillo, M P ^a   Phillips, T ^a  

^a Operational Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; APTAMER; COMPLEMENT COMPONENT C1; LIPOPOLYSACCHARIDE;

ARTICLE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG EFFECT; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ANTI-BACTERIAL AGENTS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; COMPLEMENT C1; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MOLECULAR SEQUENCE DATA; SELEX APTAMER TECHNIQUE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 51349107809     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12223-008-0046-6     Document Type: Article

References (32)

1. Alanis A.J.: Resistance to antibiotics: are we in the post-antibiotic era? Arch.Med.Res. 36, 697-705 (2005).
2. Bantroch S., Bühler T., Lam J.S.: Appropriate coating methods and other conditions for enzyme-linked immunosorbent assay of smooth, rough, and neutral lipopolysaccharides of Pseudomonas aeruginosa. Clin.Diagn.Lab.Immunol. 1, 55-62 (1994).
3. Barnes M.G., Weiss A.A.: BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect.Immun. 69, 3067-3072 (2001).
4. Boyle-Vavra S., Daum R.S.: Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab.Invest. 87, 3-9 (2007).
5. Brody E.N., Gold L.: Aptamers as therapeutic and diagnostic agents. J.Biotechnol. 74, 5-13 (2000).
6. Bruno J.G., Kiel J.L.: In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens.Bioelectron. 14, 457-464 (1999).
7. Bruno J.G., Kiel J.L.: Use of magnetic beads in selection and detection of biotoxin aptamers by ECL and enzymatic methods. Bio-Techniques 32, 178-183 (2002).
8. Cassadevall A., Dadachova E., Pirofski L.: Passive antibody therapy for infectious diseases. Nature Rev.Microbiol. 2, 695-703 (2004).
9. Chu T.C., Marks J.W., Lavery L.A., Faulkner S., Rosenblum M.G., Ellington A.D., Levy M.: Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989-5992 (2006).
10. Cload S.T., Mccauley T.G., Keefe A.D., Healy J.M., Wilson C.: Properties of therapeutic aptamers, pp. 398-399 in S. Klussmann (Ed.): The Aptamer Handbook, Chapter 17. Wiley-VCH Verlag, Weinheim (Germany) 2006.
11. Chopra I.: Research and development of antibacterial agents. Curr.Opin.Microbiol. 1, 495-501 (1998).
12. Dougan H., Lyster D.M., Vo C.V., Stafford A., Weitz J.I., Hobbs J.B.: Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl.Med.Biol. 27, 289-297 (2000).
13. Dunn D.L., Bogard W.C., Cerra F.B.: Enhanced survival during murine Gram-negative bacterial sepsis by use of a murine monoclonal antibody. Arch.Surg. 120, 50-52 (1985).
14. Dwarakanath S., Bruno J.G., Shastry A., Phillips T., John A., Kumar A., Stephenson L.D.: Quantum dot-antibody and aptamer conjugates shift fluorescence upon binding bacteria. Biochem.Biophys.Res.Comm. 325, 739-743 (2004).
15. Dwarakanath S., Satyanarayana S., Bruno J.G., Vattem D., Rao P.M., Ikanovic M., Phillips T.: Ultrasensitive fluorescent nanoparticle-based binding assays for foodborne and waterborne pathogens of clinical interest. J.Clin.Ligand Assay 29, 136-142 (2006).
16. Dwarakanath S., Bruno J.G., Athmaram T.N., Bali G., Vattem D., Rao P.: Antibody-quantum dot conjugates exhibit enhanced antibacterial effect vs. unconjugated quantum dots. Folia Microbiol. 52, 31-34 (2007).
17. Hofacker I.L.: Vienna RNA secondary structure server. Nucl.Acids Res. 31, 3429-3431 (2003).
18. Horstman A.L., Bauman S.J., Kuehn M.J.: Lipopolysaccharide 3-deoxy-D-manno-octulosonic acid (KDO) core determines bacterial association of secreted toxins. J.Biol.Chem. 279, 8070-8075 (2004).
19. Ikanovic M., Rudzinski W.E., Bruno J.G., Allman A., Carrillo M.P., Dwarakanath S., Bhahdigadi S., Rao P., Kiel J.L., Andrews C.J.: Fluorescence assay based on aptamer-quantum dot binding to Bacillus thuringiensis spores. J.Fluoresc. 17, 193-199 (2007).
20. Jayasena S.D.: Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin.Chem. 45, 1628-1650 (1999).
21. Joiner K.A., Schmetz M.A., Sanders M.E., Murray T.G., Hammer C.H., Dourmashkin R., Frank M.M.: Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc.Nat.Acad.Sci.USA 82, 4808-4812 (1985).
22. Kastowsky M., Gutberlet T., Bradaczek H.: Molecular modeling of the three-dimensional structure and conformational flexibility of bacterial lipopolysaccharide. J.Bact. 174, 4789-4806 (1992).
23. Keller M.A., Stiehm E.R.: Passive immunity in prevention and treatment of infectious diseases. Clin.Microbiol.Rev. 13, 602-614 (2000).
24. Linksmüller-Loennies S., Brade L., Brade H.: Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Internat.J.Med.Microbiol. 297, 321-340 (2007).
25. Lodowska J., Wolny D., Weglarz L., Dzierzewicz Z.: The structural diversity of lipid A from Gram-negative bacteria. Postepy Hig.Med.Dosw. 61, 106-121 (2007).
26. Mann D., Reinemann C., Stoltenberg R., Strehlitz B.: In vitro selection of DNA aptamers binding ethanolamine. Biochem.Biophys. Res.Comm. 338, 1928-1934 (2005).
27. Pan Q., Zhang X.L., Wu H.L., He P.W., Wang F., Zhang M.S., Hu J.M., Xia B., Wu J.: Aptamers that preferentially bind type IVB pilli and inhibit human monocytic-cell invasion by Salmonella enterica serovar Typhi. Antimicrob.Agents Chemother. 49, 4052-4060 (2005).
28. Santalucia J.: A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc.Nat.Acad. Sci.USA 95, 1460-1465 (1998).
29. Vivekananda J., Kiel J.L.: Anti-Francisella tularensis DNA aptamers detect tularemia antigen from different subspecies by aptamerlinked immobilized sorbent assay. Lab.Invest. 86, 610-618 (2006).
30. Wlotzka B., Leva S., Eschgfäller B., Burmeister J., Kleinjung F., Kaduk C., Muhn P., Hess-Stumpp H., Klussmann S.: In vivo properties of an anti-GnRH spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Nat.Acad.Sci.USA 99, 8898-8902 (2002).
31. Zhen B., Song Y.J., Guo Z.B., Wang J., Zhang M.L., Yu S.Y., Yang R.F.: In vitro selection and affinity function of the aptamers to Bacillus anthracis spores by SELEX. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 34, 635-642 (2002).
32. Zhong Z., Burns T., Chang Q., Carroll M., Pirofski L.: Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect.Immun. 67, 4119-4127 (1999).